CDX-005 SARS-CoV-2 Vaccine Description
CDX-005 is an intranasal, live-attenuated vaccine candidate that is generated using Codagenix’s proprietary deoptimization technology. CDX-005 is designed to produce immunity against all SARS-CoV-2 proteins, not just the spike surface protein.
Live-attenuated vaccines elicit a robust immune response and are associated with long-lasting cellular immunity. CDX-005 can be grown easily in cell culture, is scalable, and can be produced in quantities sufficient to make a significant contribution to meeting global needs.
Codagenix is a clinical-stage synthetic biology company that uses software to recode the genomes of viruses, constructing live-attenuated vaccines or viruses to prevent viral infections or treat solid tumors. Codagenix’s recoded vaccine candidates are a perfect antigenic match to the target virus and induce a robust immune response to all viral antigens.
CDX-005 SARS-CoV-2 Vaccine Indication
CDX-005 is indicated to prevent infection from SARS-CoV-2 the virus that causes COVID-19.
CDX-005 SARS-CoV-2 Vaccine News
October 19, 2020 - Serum Institute has begun manufacturing the intranasal Covid-19 vaccine, reported local media.
September 29, 2020 - A further collaboration among the Serum Institute of India (SII), the world’s largest vaccine manufacturer by volume, Gavi and the Bill & Melinda Gates Foundation will accelerate the manufacture and delivery of up to 100 million doses of safe and effective COVID-19 vaccines for India and low-and middle-income countries as part of the Gavi COVAX AMC, a mechanism within the COVAX Facility.
September 22, 2020 - Codagenix, Inc. announced that the Serum Institute of India has begun manufacturing CDX-005, the company's intranasal, live-attenuated vaccine candidate for SARS-CoV-2, the virus that causes COVID-19. Preclinical animal studies have been successfully completed, and Codagenix expects to initiate a Phase 1 first-in-human clinical trial in the UK by the end of 2020.
June 18, 2020 - Codagenix, Inc. announced the successful synthesis of a readily-scalable live-attenuated vaccine candidate against COVID-19. The vaccine, CDX-005, is currently undergoing safety and efficacy studies in animals and appears markedly attenuated compared to wild-type SARS-CoV-2, the virus that causes COVID-19, with pre-clinical data expected by early July.